A4005012
Entinostat (MS-275) , ≥98% , 209783-80-2
CAS NO.：209783-80-2
Empirical Formula: C21H20N4O3
Molecular Weight: 376.409
MDL number: MFCD08272435
| Pack Size | Price | Stock | Quantity |
| 10MG | RMB224.00 | In Stock |
|
| 50MG | RMB743.20 | In Stock |
|
| 100mg | RMB1115.20 | In Stock |
|
| 250MG | RMB2008.00 | In Stock |
|
| others | Enquire |
Update time: 2022-07-08
PRODUCT Properties
| Melting point: | 159-160 ºC |
| Boiling point: | 566.7±50.0 °C(Predicted) |
| Density | 1.315 |
| storage temp. | Keep in dark place,Sealed in dry,Store in freezer, under -20°C |
| solubility | DMSO: 38 mg/mL, soluble |
| form | solid |
| pka | 11.32±0.46(Predicted) |
| color | Pale yellow |
| Stability: | Stable for 1 year from date of purchase as supplied. Solutions in DMSO may be stored at -20° for up to 1 week. |
| InChIKey | INVTYAOGFAGBOE-UHFFFAOYSA-N |
Description and Uses
Entinostat (SNDX-275, MS-275) belongs to benzamide class HDACi and inhibits HDAC1 and 2, 3 and 9 and has low effect against HDAC4, 6, 7 and 8 (Khan et al. 2007). Entinostat is in phase II clinical trial for treatment of Hodgkin's lymphoma and advanced breast cancer (in combination with aromatase inhibitors) and metastatic lung cancer (in combination with erlotinib).
Entinostat is an emerging HDACi (histone deacetylase inhibitor). Entinostat is used for treatment of solid tumors and hematologic malignancies. Potent Histone deacetylase inhibitor.
Safety
| Symbol(GHS) |   GHS06,GHS08 |
| Signal word | Danger |
| Hazard statements | H301-H360 |
| Precautionary statements | P201-P301+P310+P330 |
| Hazard Codes | Xi,T |
| Risk Statements | 36/37/38-62-48/25-25-61 |
| Safety Statements | 26-36-45 |
| RIDADR | UN 2811 6.1 / PGIII |
| WGK Germany | 3 |
| HS Code | 29333990 |
